Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

180.32 +2.88 (+1.62%)
Streaming Delayed Price Updated: 3:11 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
80 81 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?
AbbVie is committed to rewarding shareholders, even during tough times. 
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
3 Dividend Stocks That Are Perfect for Beginning Investors
For new market participants, these dividend stocks for beginners should steer your portfolio in the right direction. 
Via InvestorPlace
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
Looking Into AbbVie's Recent Short Interest
Via Benzinga
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Guidance leads the market for these stocks; 1 raises, 1 lowers
Guidance is a driving force for equity markets and can lead stock prices higher or lower, catalyze significant moves, and alter analysts' outlook 
Via MarketBeat
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
The company tested its drug over 12 weeks in 207 patients. All but one regimen led to statistically significant improvements. 
Via Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
Income investors should find plenty to like with these stocks. 
Via The Motley Fool
Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever
Dividend stocks can cushion your portfolio in times of market trouble. 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
It just had a brutal quarter, and it might have a couple more on the way. 
Via The Motley Fool
Top 5 Dividend Stocks In My $4 Million Portfolio (With Growth Potential In 2024)
In this blog post, we’re going to explore the world of dividend stocks and I’ll share my top five picks. 
Via Talk Markets
Meet the Next Trillion-Dollar Companies: Our Top 3 Picks
Of the current five trillion-dollar companies, several more are within shouting distance. Here are our top three picks to get there. 
Via InvestorPlace
EXCLUSIVE: Roundhill Launches Dividend Kings ETF With 'The Gold Standard Of Dividend Growers,' Companies With 'Incredible Resilience'
A new ETF offers investors exposure to companies with long streaks of raising their dividends. 
Via Benzinga
Topics ETFs
3 Dividend Stocks That Are Investor Safe Havens
If there is such a thing as safe dividend stocks, these three should be at the top of your list to consider. 
Via InvestorPlace
3 Dividend Stocks That Can Power Your Portfolio for Decades
From healthcare to home repair to tech, these stocks can help diversify your holdings. 
Via The Motley Fool
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
Via InvestorPlace
Pfizer Posted a Steep Loss. Is It Time to Sell?
A $5.6 billion inventory write-down isn't what investors wanted to see, but this company is made of many moving pieces. 
Via The Motley Fool
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
AbbVie has a head start, but that might not be enough to save its top line. 
Via The Motley Fool
Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why
Amgen Inc (NASDAQ: AMGN) reported Q3 FY23 sales of $6.90 billion, slightly missin 
Via Benzinga
J&J stock down as business unit mulls talc-related bankruptcy
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements. 
Via MarketBeat
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Is AbbVie Still a Good Dividend Stock to Buy?
The decline in sales of Humira, AbbVie's top seller, is enough to make anyone nervous. 
Via The Motley Fool
Why AbbVie Stock Was a Winner on Monday
One analyst tracking the pharmaceutical major upgraded his recommendation. 
Via The Motley Fool
AbbVie Analysts Increase Their Forecasts After Upbeat Earnings
AbbVie Inc (NYSE: ABBV) reported better-than-expected earnings for its third quarter and raised its profit outlook on Friday. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.